# Genentech, Inc.: Phase 2 study in Geographic Atrophy Secondary to Age-Related Macular Degeneration (321 participants)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Genentech, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration |
| NCT ID | NCT07851259 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | Geographic Atrophy Secondary to Age-Related Macular Degeneration |
| Intervention types | drug |
| Target enrollment | 321 |
| Site countries | United States |
| Posted | 2026-10-01 |
| Planned start | 2027-01-08 |
| Event | Newly registered study |
| Event date | 2026-10-01 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 2: multi-site, larger budget.
- 321 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07851259). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.